TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17803164

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 15067204

Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg per os)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) (40 mg per os)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) (40 mg per os) during hyperprolactinemia
Number of subjects: 11

Group type: COMPARATOR
Intervention: Hydrocortisone (HC) alone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) during hyperprolactinemia
Number of subjects: 11
Study: 11440295

Group type: EXPERIMENTAL
Intervention: Nicotine inhalers, duration of smoking abstinence categorized as recidivists (0 days smoke free), short-term abstainers (1-7 days smoke free), or longer-term abstainers (>7 days smoke free)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recidivists (0 days smoke free)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer-term abstainers (>7 days smoke free)
Number of subjects: 0
Study: 9663811

Group type: EXPERIMENTAL
Intervention: ACE inhibitor preparations
Number of subjects: 132
Study: 7820329

Group type: EXPERIMENTAL
Intervention: E3810 single oral doses (1, 3, 10, 20, 40 and 80 mg) in fasting conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E3810 single oral dose (20 mg) after a meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E3810 repeated oral doses (20 and 40 mg) once daily for 7 days
Number of subjects: 0
Study: 3138444

Group type: EXPERIMENTAL
Intervention: 3-in-1 admixture TPN
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional TPN
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 200
Study: 28780685

Group type: EXPERIMENTAL
Intervention: Web-based health education program
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 55
Study: 27957596

Group type: EXPERIMENTAL
Intervention: Biodegradable inflatable InSpace™ system
Number of subjects: 24
Study: 26100824

Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg single dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24229676

Group type: EXPERIMENTAL
Intervention: T80/H25
Number of subjects: 888

Group type: COMPARATOR
Intervention: T80
Number of subjects: 888
Study: 21724872

Group type: EXPERIMENTAL
Intervention: Daikenchuto (TJ‐100) 5-g administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daikenchuto (TJ‐100) 2.5 to 10 g/day
Number of subjects: 0
Study: 18805510

Group type: EXPERIMENTAL
Intervention: Breastfeeding intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17165237

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 100
Study: 15274666

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg daily and tinidazole 500 mg two tablets daily with lansoprazole 30 mg daily for 6 days (ATL-group)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo with tinidazole and azithromycin (ATP-group)
Number of subjects: 131
Study: 11071674

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.3 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.14 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (intravenous and intrathecal)
Number of subjects: 30
Study: 8871173

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg) in supplementary experiments
Number of subjects: 15
Study: 1386245

Group type: EXPERIMENTAL
Intervention: Loading dose of 8 mg of ondansetron followed by a 24 h infusion of 1 mg h‐1 (group 1)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Single dose of 32 mg of ondansetron (group II)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Single dose of 8 mg of ondansetron (group III)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Comparison of ondansetron efficacy based on gender
Number of subjects: 535
Study: 6370981

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 29314146

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) 400 mg + Daclatasvir (DCV) 60 mg daily + weight-based Ribavirin (RBV) for 12 weeks (or 24 weeks if RBV contraindicated)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Daclatasvir (DCV) + Ribavirin (RBV)
Number of subjects: 551
Study: 29121974

Group type: EXPERIMENTAL
Intervention: Minocycline added to treatment as usual (TAU)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids added to treatment as usual (TAU)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Minocycline and/or omega-3 fatty acids added to treatment as usual (TAU)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 320
Study: 26414968

Group type: EXPERIMENTAL
Intervention: Spironolactone (25-50 mg)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335

Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 335

Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 335
Study: 24067210

Group type: EXPERIMENTAL
Intervention: Rehabilitation exercise combined with encouragement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 120
Study: 20864558

Group type: EXPERIMENTAL
Intervention: Moderate packing (0.79 ± 0.40 liters)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No packing (control)
Number of subjects: 14
Study: 18174758

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention for older smokers (62 and older)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Smoking cessation intervention for younger smokers (under 62)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Statistical analysis of smoking cessation rates
Number of subjects: 277
Study: 16808827

Group type: EXPERIMENTAL
Intervention: Power Doppler Imaging (PDI) protocol
Number of subjects: 76

Group type: COMPARATOR
Intervention: Continuous wave (cw) Doppler protocol
Number of subjects: 76
Study: 12496541

Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal laparoscopic repair
Number of subjects: 994

Group type: COMPARATOR
Intervention: Conventional anterior hernia repair
Number of subjects: 994
Study: 10404850

Group type: EXPERIMENTAL
Intervention: Immediate-release ranolazine (various dosing regimens)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 7562112

Group type: EXPERIMENTAL
Intervention: HMF (undigested high molecular fraction of soybean protein)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Casein
Number of subjects: 0
Study: 2185298

Group type: EXPERIMENTAL
Intervention: Daily paracentesis (3‐4 litre) and intravenous albumin infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ascites recirculation (Rhodiascit apparatus)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ascites recirculation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Daily paracentesis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ascites recirculation and daily paracentesis
Number of subjects: 40
Study: 7387803

Group type: EXPERIMENTAL
Intervention: Calcium chloride (10 ml of a 10% solution, containing elemental calcium 27 mg ml‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Calcium gluceptate (20 ml, containing elemental calcium 18 mg ml‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Calcium chloride
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Calcium gluceptate
Number of subjects: 10
Study: 30834520

Group type: EXPERIMENTAL
Intervention: Concurrent exposure to maternal socioeconomic and psychosocial indicators of adversity
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Longitudinal exposure to maternal stress symptoms
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Cumulative adversity count
Number of subjects: 319
Study: 28061830

Group type: EXPERIMENTAL
Intervention: Geriatric intervention involving systematic preoperative geriatric assessment and adjusted nutritional support according to guidelines.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 0
Study: 26594847

Group type: EXPERIMENTAL
Intervention: Seizure Freedom (SF) group
Number of subjects: 73

Group type: COMPARATOR
Intervention: Not Seizure-Free (NSF) group
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study: 24498939

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) delivered by respiratory nurses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-help leaflets
Number of subjects: 0
Study: 22014222

Group type: EXPERIMENTAL
Intervention: Internet-based multimedia program
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 164
Study: 19408480

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allograft (ADMA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 32
Study: 17519560

Group type: EXPERIMENTAL
Intervention: 2% Ectoin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Vehicle emulsion
Number of subjects: 104

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 104
Study: 15365226

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 52
Study: 11463510

Group type: EXPERIMENTAL
Intervention: Levetiracetam (2000 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 9711471

Group type: EXPERIMENTAL
Intervention: Bromazepam 1.5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9075195

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 172
Study: 2036817

Group type: EXPERIMENTAL
Intervention: Formoterol (F)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Salbutamol (S)
Number of subjects: 13
Study: 6938259

Group type: EXPERIMENTAL
Intervention: Filtration leukapheresis
Number of subjects: 48

Group type: COMPARATOR
Intervention: Gravity leukapheresis
Number of subjects: 48
Study: 31852411

Group type: EXPERIMENTAL
Intervention: Structured semi-interactive stroke prevention package (includes a stroke prevention workbook, regular educational short messages, and videos)
Number of subjects: 5830

Group type: COMPARATOR
Intervention: Standard of care management
Number of subjects: 5830
Study: 30734359

Group type: EXPERIMENTAL
Intervention: Case vignettes for oral healthcare management
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Best practice or evidence-based recommendations
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Confidence in recognizing symptoms
Number of subjects: 1244
Study: 29072020

Group type: EXPERIMENTAL
Intervention: Xingnao Kaiqiao needling stimulation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 140
Study: 26679702

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation, 3g/d of EPA and DHA for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PL, olive oil) for 12 weeks
Number of subjects: 24
Study: 23926585

Group type: EXPERIMENTAL
Intervention: Sonic toothbrush (Philips Sonicare FlexCare® toothbrush)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Manual toothbrush (Oral‐B P40®)
Number of subjects: 83
Study: 22002187

Group type: EXPERIMENTAL
Intervention: Mckenzie technique
Number of subjects: 18
Study: 18541517

Group type: EXPERIMENTAL
Intervention: Hypoxia-targeted therapeutics (e.g., tirapazamine, AQ4N)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chemotherapeutic agents
Number of subjects: 0
Study: 17162245

Group type: EXPERIMENTAL
Intervention: UDCA 12-15 mg.kg-1.day-1 with vitamin E 400 IU twice a day (UDCA/Vit E)
Number of subjects: 48

Group type: COMPARATOR
Intervention: UDCA with placebo (UDCA/P)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo/placebo (P/P)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: UDCA/Vit E
Number of subjects: 48
Study: 12662277

Group type: EXPERIMENTAL
Intervention: Non-WBC-reduced RBC transfusion
Number of subjects: 523

Group type: COMPARATOR
Intervention: WBC-reduced RBC transfusion
Number of subjects: 523
Study: 10892946

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted blood cardioplegia (LDBCP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Blood cardioplegia (BCP)
Number of subjects: 50
Study: 8725891

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) before radical prostatectomy
Number of subjects: 0
Study: 1920343

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg
Number of subjects: 0
Study: 6226187

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30528725

Group type: EXPERIMENTAL
Intervention: .5% bupivacaine
Number of subjects: 41

Group type: COMPARATOR
Intervention: .9% NaCl (control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 41
Study: 27844224

Group type: EXPERIMENTAL
Intervention: Minimally invasive medial maxillectomy approach through the lacrimal recess
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Narrow lacrimal recess (less than 4 mm)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Missing lacrimal recess
Number of subjects: 125

Group type: COMPARATOR
Intervention: Narrow lacrimal recess
Number of subjects: 125
Study: 26958746

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure-lowering therapy (target systolic blood pressure, < 140 mm Hg within 1 hr)
Number of subjects: 3243

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure-lowering therapy (target systolic blood pressure, < 180 mm Hg)
Number of subjects: 3243
Study: 24931951

Group type: EXPERIMENTAL
Intervention: 3-drug therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: monotherapy
Number of subjects: 0
Study: 22383748

Group type: EXPERIMENTAL
Intervention: Non-Hispanic blacks with CKD not requiring dialysis
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Non-Hispanic whites with CKD not requiring dialysis
Number of subjects: 1497

Group type: EXPERIMENTAL
Intervention: Blacks with CKD not requiring dialysis
Number of subjects: 1497

Group type: EXPERIMENTAL
Intervention: Blacks with CKD and ESRD
Number of subjects: 1497
Study: 19438129

Group type: EXPERIMENTAL
Intervention: 2700 CGy in 5 fractions (one week)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 3500 CGy in 10 fractions (2 weeks)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 4000 CGy in 15 fractions (3 weeks)
Number of subjects: 300
Study: 17486919

Group type: EXPERIMENTAL
Intervention: remifentanil pTCI
Number of subjects: 28

Group type: COMPARATOR
Intervention: remifentanil eTCI
Number of subjects: 28
Study: 14990551

Group type: EXPERIMENTAL
Intervention: High-force eccentric contractions
Number of subjects: 9
Study: 12235451

Group type: EXPERIMENTAL
Intervention: Lercanidipine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 40
Study: 9521221

Group type: EXPERIMENTAL
Intervention: Atorvastatin (Lipitor) at dosages of 10 to 80 mg/d
Number of subjects: 4271
Study: 7986114

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy of CDDP+VDS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDDP and 5‐FU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery + postoperative chemotherapy with CDDP+5‐FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemo‐radiotherapy
Number of subjects: 0
Study: 2736615

Group type: EXPERIMENTAL
Intervention: Subcutaneous group (I)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intradermal group (II)
Number of subjects: 120
Study: 4923653

Group type: EXPERIMENTAL
Intervention: L-dopa (10 weeks treatment)
Number of subjects: 34
Study: 31222468

Group type: EXPERIMENTAL
Intervention: Radiomics signature for overall survival (OS)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Radiomics signature for progression-free survival (PFS)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Radiomics signature for local control (LC)
Number of subjects: 110
Study: 29208255

Group type: EXPERIMENTAL
Intervention: Ice cream test
Number of subjects: 104

Group type: COMPARATOR
Intervention: 75-g OGTT
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ice cream test and 75-g OGTT
Number of subjects: 104
Study: 26323697

Group type: EXPERIMENTAL
Intervention: Higher heart rate (71-117 beats/min)
Number of subjects: 5042

Group type: EXPERIMENTAL
Intervention: Lower SDNN (1.70-13.30 ms)
Number of subjects: 5042
Study: 23614585

Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 691

Group type: COMPARATOR
Intervention: Right ventricular pacing
Number of subjects: 691
Study: 21223551

Group type: EXPERIMENTAL
Intervention: Aspirin (trial medication)
Number of subjects: 28

Group type: COMPARATOR
Intervention: N/A (participants who declined to participate)
Number of subjects: 28
Study: 19127470

Group type: EXPERIMENTAL
Intervention: Permutation test following Pocock‐Simon's covariate‐adaptive randomization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional population‐based tests
Number of subjects: 0
Study: 16829885

Group type: EXPERIMENTAL
Intervention: Completion of the Modified Dental Anxiety Scale
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Completion of the state anxiety assessment only
Number of subjects: 1004
Study: 12729348

Group type: EXPERIMENTAL
Intervention: First dose of BCG vaccination
Number of subjects: 71341

Group type: EXPERIMENTAL
Intervention: Second dose of BCG vaccination
Number of subjects: 71341
Study: 11079287

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention with home blood pressure monitoring
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 36
Study: 9296529

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 3 IU/m2 per day for group 1 (n=6)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 4.5 IU/m2 per day for group 2 (n=6)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 3 IU/m2 per day in the 1st year and 4.5 IU/m2 per day thereafter for group 3 (n=5)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 4 years (14 children) and 5 years (8 children)
Number of subjects: 17
Study: 8326054

Group type: EXPERIMENTAL
Intervention: Behavioral couple therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of behavioral couple therapy and cognitive-behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Husbands' facilitative behavior
Number of subjects: 0
Study: 3709072

Group type: EXPERIMENTAL
Intervention: Simple short term prescribed diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 12
Study: 29855838

Group type: EXPERIMENTAL
Intervention: Doula-home-visiting services
Number of subjects: 312

Group type: COMPARATOR
Intervention: Case management
Number of subjects: 312
Study: 27398703

Group type: EXPERIMENTAL
Intervention: GWG above IOM guidelines
Number of subjects: 293

Group type: COMPARATOR
Intervention: GWG within IOM guidelines
Number of subjects: 293
Study: 24857719

Group type: EXPERIMENTAL
Intervention: Chewing food 40 times before swallowing
Number of subjects: 15

Group type: COMPARATOR
Intervention: Chewing food 15 times before swallowing
Number of subjects: 15
Study: 23158712

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus methylprednisolone
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control (methylprednisolone alone)
Number of subjects: 156
Study: 20937977

Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.5 mg/d
Number of subjects: 8556

Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.25 mg/d
Number of subjects: 8556

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8556
Study: 18341545

Group type: EXPERIMENTAL
Intervention: Individual treatment
Number of subjects: 127

Group type: COMPARATOR
Intervention: Group treatment
Number of subjects: 127
Study: 16253807

Group type: EXPERIMENTAL
Intervention: Endurance-trained subjects; Distribution volume of [11C]TMSX in myocardium: 3.6+/‐0.3 ml g(‐1); Triceps brachii muscle: 1.7+/‐0.3 ml g(‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untrained subjects; Distribution volume of [11C]TMSX in myocardium: 3.1+/‐0.4 ml g(‐1); Triceps brachii muscle: 1.2+/‐0.2 ml g(‐1)
Number of subjects: 10
Study: 12142983

Group type: EXPERIMENTAL
Intervention: Selenium-based digital radiography
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional screen-film radiography
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparison of selenium-based digital radiography and conventional screen-film radiography
Number of subjects: 25
Study: 10433668

Group type: EXPERIMENTAL
Intervention: Patient handwashing education model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no patient education)
Number of subjects: 0
Study: 8519712

Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Alkalinized mepivacaine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Alkalinized bupivacaine
Number of subjects: 180
Study: 1694294

Group type: EXPERIMENTAL
Intervention: Aspartame (34 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sucrose (1.75 g/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aspartame (9.7 mg/kg)
Number of subjects: 20
Study: 795779

Group type: EXPERIMENTAL
Intervention: Penfluridol
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 47